Khiron Life Sciences Expands CBD-Based Wellness Product Portfolio With Additional Authorizations from Colombian National Food and Drug Surveillance Institute (INVIMA)
Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV:KHRN), a Canadian integrated medical cannabis company with its core operations in Colombia, announced today that further to its announcement of May 30, 2018, the Colombia National Food and Drug Surveillance Institute (“INVIMA”) has granted Khiron authorization for the production, sale and export of four additional cannabidiol (“CBD”) based products for skin and body care.
With the addition of these four new products, Khiron now has authorization to commercialize eight products, strengthening its position as a medicinal cannabis industry first-mover in Colombia and Latin America.
The additional products approved by INVIMA expands Khiron’s portfolio of products operating under its wellness business unit, which aims to target the growing skin care market in Colombia, a market of over CAD 530 Million in annual sales with growth of over 6% per year over the past 5 years.
“As we move to bring cannabis-based skin care products, in addition to medical cannabis, to market, we appreciate the essential support that this authorization by INVIMA provides. We see tremendous opportunity to lead the cannabis-based wellness product sector, a category with untapped potential to meet consumer needs using natural, innovative ingredients with proven scientific results.” comments Andrés Galofre, VP Marketing and Sales at Khiron.
This CBD product line will provide women and men with a full collection of medicinal skin care solutions for each stage of their daily skincare routine, from early morning through to pre-sleep. The first wellness product is anticipated by Q4 2018, with initial distribution in Colombia, and commercialization potential across Latin America.
“We are very pleased with the progress made by our wellness business unit towards bringing quality, trusted medically and scientifically validated cannabis-based personal care products to consumers in Colombia and Latin America. We see outstanding growth potential in this area, backed by our growing reputation as the medical cannabis leader in Colombia, and across the region.” says Alvaro Torres, CEO of Khiron Life Sciences Corp.
INVIMA, established by the Colombian Ministry of Health to inspect and supervise the production and marketing of health products in the country is a leader in the region, holding level four status with the World Health Organization (WHO).
About Khiron Life Sciences Corp.
Khiron Life Sciences is a Canadian integrated medical cannabis company with its core operations in Colombia. Khiron combines leading international scientific expertise, agricultural advantages and branded product market entrance experience to address the unmet medical needs in a market of over 620 million people in Latin America. Khiron has received licenses in Colombia for high- and low-tetrahydrocannabinol (THC) medical cannabis, and has received all licenses required for the cultivation, production, domestic distribution, and international export of both THC and cannabidiol (CBD) medical cannabis. Khiron Life Sciences Corp. lists on the Toronto Venture Exchange: TSXV: KHRN
Further information on the Company can be accessed at: www.khiron.ca
SOURCE Khiron Life Sciences Corp.
For further information: Darren Collins, Chief Financial Officer, T: +1 (705) 527-3564, E: firstname.lastname@example.org; Canada Investor Relations, Nicole Marchand, GRIT Capital, T: +1 (416) 428-3533, E: email@example.com; U.S. Investor Relations, Lisa Wilson, In-Site Communications, Inc., T: +1 (917) 543-9932, E: firstname.lastname@example.org
CanBud Distribution Corporation Closes 2M Second and Final Tranche of its Oversubscribed Private Placement Offering
CanBud Distribution Corporation (CSE: CBDX) (FSE: CD0) (“CanBud” or the “Corporation”) is pleased to announce that it has closed the final tranche of its oversubscribed non-brokered private placement for aggregate gross proceeds of approximately $4,730,000 (the “Offering”).
The Corporation issued a combined total of 39,409,346 units (each a “Unit“) at price of $0.12 per Unit, with each Unit comprised of one common share in the capital of the Corporation (each a “Common Share“) and one common share purchase warrant (each a “Warrant“). Each Warrant entitles the holder to purchase one additional Common Share at an exercise price of $0.22 within 24 months of the closing of the Offering (the “Warrant Term“), provided, however that if the closing price of the Common Shares on the Canadian Securities Exchange (the “CSE“) (or any such other stock exchange in Canada as the Common Shares may trade at the applicable time) is $0.25 or greater per Common Share for a period of five (5) consecutive trading days at any time after the closing date of the Offering, the Corporation may accelerate the Warrant Term such that the Warrants shall expire on the date which is 30 days following the date a press release is issued by the Corporation announcing the reduced warrant terms.
Thoughtful Brands Inc. (CSE:TBI)(FSE:1WZ1)(OTCQB:PEMTF) (the “Company” or “Thoughtful Brands) announces that the letter of intent with Franchise Cannabis Corp. (“FCC”), previously announced in January, has been terminated. The previously announced European joint venture with FCC will continue and allow the Company to launch and tailor its products to European consumer demands
In connection with termination of the merger transaction with FCC, the Company has agreed to pay FCC $100,000 in cash and to issue FCC 5,000,000 common shares of the Company at a deemed value of $0.05 per share. The common shares will be subject to a four-month-and-one-day statutory hold period in accordance with applicable securities laws.
Mergers and acquisitions (M&A) in cannabis space have helped boost the industry to new levels.
Strategic sale of non-core assets by Lobe adds non-dilutive capital and shareholder value
Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce, further to its press release dated February 23, 2021, that it has completed the sale to Ionic Brands Corp. (“Ionic Brands”) of Lobe’s non-core cannabis assets relating to Washington-based Cowlitz County Cannabis Cultivation Inc. (“Cowlitz”) held by Lobe’s subsidiary vendor, Green Star Biosciences Inc. (the “Transaction”).
Seattle Area Grocery Chain Metropolitan Market to Begin Carrying KOIOS and Fit Soda on March 22, 2021
Adding to its existing presence on the west coast of the United States, all five KOIOS™ flavours and all four Fit Soda™ flavours will be carried in Metropolitan Market stores beginning on Monday, March 22, 2021. Serving the Seattle-Tacoma area (population 3.87 million), Metropolitan Market is one of five chains under its parent firm Good Food Holdings, which has a total of 51 stores in California, Oregon, and Washington State.
Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that beginning on Monday, March 22, 2021, Koios’ entire line of canned beverage products will be sold at all locations of Metropolitan Market, an urban format supermarket chain in the Seattle-Tacoma area of Washington State. In Q1 2021, the Company announced multiple placements of its beverage products with regional grocers in markets on the west coast of the United States including Market of Choice in Oregon Jensen’s in Southern California and major natural grocery chain Sprouts Farmers Market which has a substantial west coast presence with over one third of its locations (360+ stores across 23 states) in California as well as Washington State 1 . The Company has also recently announced other developments relating to its expansion efforts being undertaken in 2021 such as an in-house beverage canning facility and distribution agreements with regional and national wholesale partners.